Notably, targeted inhibition of NRF2 with Brusatol counteracts this effect, effectively suppressing NRF2 activity and inducing apoptosis in breast cancer cells both in vitro and in vivo [170]. This evidence concerns the gene NFE2L2 and breast carcinoma.